![Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00030/asset/images/large/jm2c00030_0014.jpeg)
Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance | Journal of Medicinal Chemistry
![Current Oncology | Free Full-Text | Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors Current Oncology | Free Full-Text | Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors](https://www.mdpi.com/curroncol/curroncol-28-00223/article_deploy/html/images/curroncol-28-00223-g001.png)
Current Oncology | Free Full-Text | Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives | Journal of Medicinal Chemistry
![PDF) CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes PDF) CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes](https://i1.rgstatic.net/publication/8656256_CD100Plexin-B1_interactions_sustain_proliferation_and_survival_of_normal_and_leukemic_CD5_B_lymphocytes/links/00b7d528dc6abb37d7000000/largepreview.png)
PDF) CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes
![Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection](https://pub.mdpi-res.com/cancers/cancers-14-00281/article_deploy/html/images/cancers-14-00281-g001.png?1652172831)
Cancers | Free Full-Text | Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection
![PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients](https://i1.rgstatic.net/publication/354966383_Cardiovascular_adverse_events_in_patients_with_chronic_lymphocytic_leukemia_receiving_acalabrutinib_monotherapy_pooled_analysis_of_762_patients/links/6155f131e7bb415a5d4393a5/largepreview.png)
PDF) Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
![Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia - ScienceDirect Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120557091-gr3.jpg)
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia - ScienceDirect
![Cancers | Free Full-Text | Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia Cancers | Free Full-Text | Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia](https://pub.mdpi-res.com/cancers/cancers-14-01715/article_deploy/html/images/cancers-14-01715-g001.png?1648468284)
Cancers | Free Full-Text | Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
![Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence | Science Translational Medicine Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.aal1571/asset/091e352e-c732-4f6b-99a9-88b4c1f8b314/assets/graphic/aal1571-f1.jpeg)